<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04754295</url>
  </required_header>
  <id_info>
    <org_study_id>CT0012021</org_study_id>
    <nct_id>NCT04754295</nct_id>
  </id_info>
  <brief_title>Goal-directed Therapy in Neurosurgery.</brief_title>
  <official_title>Effect of Goal-directed Fluid Management Guided by Non-invasive Device on Incidence of Postoperative Complications in Neurosurgery: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brno University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess feasibility of future large randomised controled study&#xD;
      aimed on assessment of effect of goal-directed therapy on incidence of complications in&#xD;
      neurosurgery compared to standard care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing neurosurgical operations are at risk of inadequate intravascular volume&#xD;
      for several reasons. The appropriate fluid management in neurosurgery is a challenge.&#xD;
      Goal-directed therapy has been shown to improve the outcome of patients undergoing major&#xD;
      surgery. Current knowledge regarding effect of fluid management on patient-orientated&#xD;
      outcomes in neurosurgery is limited.&#xD;
&#xD;
      This study is designed as a pilot study with two parallel groups. Patients scheduled to&#xD;
      planned brain surgery at the University Hospital Brno will be screened whether they meet the&#xD;
      inclusion criteria. After obtaining informed consent, the patient will be randomized to one&#xD;
      of the study arms.&#xD;
&#xD;
      In one arm (STANDARD) standard monitoring of vital signs will be introduced. During the&#xD;
      operation, perioperative fluid therapy and administration of vasoactive agents will depend&#xD;
      entirely at the discretion of the attending anaesthetist. Postoperative therapy will be fully&#xD;
      controlled and will depend on the decision of the attending physician. In the second arm&#xD;
      (GDT), a non-invasive hemodynamic monitor STARLINK™SV will be introduced in addition to&#xD;
      standard monitoring. In this arm, basal infusion with crystalloid balanced solution will be&#xD;
      initiated. Additional boluses of fluids will be administered based on haemodynamic&#xD;
      monitoring. The primary outcome of the study is a proportion of patients with serious adverse&#xD;
      event (SAE). Incidence of SAEs will be compared between study groups. SAE will be defined as&#xD;
      unsatisfactory brain tissue relaxation at the end of operation and any intervention for brain&#xD;
      oedema postoperatively.&#xD;
&#xD;
      The secondary outcome is to compare proportion of patients with postoperative complications&#xD;
      in both groups and length of ICU and hospital stay.&#xD;
&#xD;
      This study will enroll 34 patients in total, 17 in each group. After completion of enrolment&#xD;
      of patients the statistical analysis will be performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Events 1</measure>
    <time_frame>During the Surgery</time_frame>
    <description>Assessment of number of patients with serious adverse event (SAE). SAE is defined as unsatisfactory brain tissue relaxation at the end of surgery assessed by neurosurgeon. Level 3 or 4 of brain tissue relaxation will be considered as unsatisfactory (level 1 - completely relaxed, level 2 - satisfactorily relaxed, level 3 - firm, level 4 - bulging).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious Adverse Events 2</measure>
    <time_frame>24 hours postoperatively</time_frame>
    <description>Assessment of number of patients with serious adverse event (SAE). SAE is defined as any intervention indicated for treatment of brain edema 24 hours after surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Proportion of eligible patients who consent to participate in the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Completeness of Case Report Forms</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Proportion of enrolled patients with completed Case Report Form.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>through study completion, an average of 6 months</time_frame>
    <description>Number of patients with pre-defined postoperative complication.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Surgery--Complications</condition>
  <arm_group>
    <arm_group_label>STANDARD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this arm standard monitoring of vital signs will be used during operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A non-invasive hemodynamic monitor STARLINK™SV will be used in addition to standard monitoring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Goal-Directed Therapy</intervention_name>
    <description>Administration of fluids and vasoactive drugs guided by non-invasive haemodynamic monitoring</description>
    <arm_group_label>GDT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>STANDARD</intervention_name>
    <description>Administration of fluids and vasoactive drugs guided by standard vital signs monitoring</description>
    <arm_group_label>STANDARD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age at least 18 years&#xD;
&#xD;
          -  anticipated duration of surgery at least 2 hours&#xD;
&#xD;
          -  signed written consent form&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) classification &lt; 4.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unavailability of hemodynamic monitor&#xD;
&#xD;
          -  emergency operation&#xD;
&#xD;
          -  ASA ≥4&#xD;
&#xD;
          -  sitting operating position and awake craniotomy&#xD;
&#xD;
          -  awake craniotomy&#xD;
&#xD;
          -  serious cardiorespiratory disorder&#xD;
&#xD;
          -  cardiac arrythmia&#xD;
&#xD;
          -  obesity with BMI above 35 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Gal, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masaryk University Brno and University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ondrej Hrdy, M.D.</last_name>
    <phone>532233850</phone>
    <phone_ext>+420</phone_ext>
    <email>hrdy.ondrej@fnbrno.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roman Gal, M.D., Ph.D.</last_name>
    <phone>532233847</phone>
    <phone_ext>+420</phone_ext>
    <email>gal.roman@fnbrno.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roman Gal, M.D., Ph.D.</last_name>
      <phone>532233850</phone>
      <phone_ext>+420</phone_ext>
      <email>gal.roman@fnbrno.cz</email>
    </contact>
    <contact_backup>
      <last_name>Ondrej Hrdy, M.D.</last_name>
      <phone>532232305</phone>
      <phone_ext>+420</phone_ext>
      <email>hrdy.ondrej@fnbrno.cz</email>
    </contact_backup>
    <investigator>
      <last_name>Roman Gal, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ondrej Hrdy, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Hlavaty, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Milos Duba, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrea Dolezelova, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MArtin Smrcka, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2021</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brno University Hospital</investigator_affiliation>
    <investigator_full_name>Ondrej Hrdy</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Neurosurgery</keyword>
  <keyword>Goal-Directed Therapy</keyword>
  <keyword>Complications</keyword>
  <keyword>Pilot study</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

